Genenta Science announced that it has signed definitive agreements with Sophia High Tech, marking a strategic expansion into the aerospace and defense sector as part of its broader transformation into an industrial consolidator.
Under the agreement, Genenta will invest a total of €6 million in two tranches to acquire a controlling position in Sophia High Tech. The first tranche will provide a 19.9% stake, while completion of the second tranche will increase ownership to 51%, making the company a majority-owned subsidiary.
Sophia High Tech manufactures precision mechanical components used in European space and defense programs, supplying organizations such as the European Space Agency and major aerospace contractors. The company reported approximately €6.29 million in revenue and €0.96 million in EBITDA in 2024 and is expected to generate around €8 million in sales in 2025, reflecting steady growth and a profitable operating profile.
The investment proceeds are expected to support production scaling, automation, and technological development, while strengthening the company’s commercial footprint. Genenta also plans to contribute operational expertise, financial controls, and strategic oversight to accelerate growth and improve efficiency.
This transaction is a key milestone in Genenta’s evolution beyond its biotech roots, as it builds a diversified platform across biotech, defense, aerospace, and national security technologies. The company has been actively repositioning itself to pursue industrial consolidation opportunities in strategic sectors tied to economic resilience and national security.
Sophia High Tech is expected to benefit from increased access to capital and institutional demand channels, with plans to expand its workforce and scale operations over the coming years. The company aims to roughly double its 2024 revenue base by 2027 while increasing headcount from about 44 employees to around 70.
The deal underscores a broader trend of cross-sector convergence, where companies with origins in biotechnology and advanced research are increasingly expanding into adjacent industries such as aerospace and defense to capture new growth opportunities and diversify revenue streams.
The transaction remains subject to customary closing conditions, including regulatory approvals.
